1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Antidepressants (Migraine) - Forecast and Market Analysis to 2023

Antidepressants (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Certain Antidepressants have been used for the treatment of migraine since the 1970s (Gomersall and Stuart, 1973). Several classes of antidepressants exist, each with a different mechanism of action. These include tricyclic antidepressants (TCAs), MAO inhibitors, selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). Although the mechanism by which antidepressants prevent migraine headache is unknown, improvement is independent from treating masked depression; the response occurs sooner than the antidepressive effect.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Antidepressants including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Antidepressants for the top five countries from 2012 to 2023.
- Sales information covered for the US, France, Italy, Spain and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Antidepressants performance
- Obtain sales forecast for Antidepressants from 2012-2023 in the top five countries (the US, France, Italy, Spain and Japan)

Table Of Contents

Antidepressants (Migraine) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16
3.2.1 Premonitory Phase 17
3.2.2 Aura Phase 17
3.2.3 Headache Phase 18
3.2.4 Postdrome Phase 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Treatment 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Antidepressants 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 28
6.4 SWOT Analysis 28
6.5 Forecast 28
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 33
7.3 Methodology 34
7.4 Forecasting Methodology 34
7.4.1 Diagnosed Migraine Patients 35
7.4.2 Percent Drug-treated Patients 35
7.4.3 General Pricing Assumptions 35
7.4.4 Individual Drug Assumptions 36
7.4.5 Generic Erosion 36
7.5 Physicians and Specialists Included in this Study 37
7.6 Survey of Prescribing Physicians 38
7.7 About the Authors 39
7.7.1 Author 39
7.7.2 Reviewer 39
7.7.3 Global Head of Healthcare 40
7.8 About GlobalData 41
7.9 Disclaimer 41

1.1 List of Tables

Table 1: Classification of Migraine Subtypes 13
Table 2: Diagnostic Criteria for Migraine with Aura 17
Table 3: Diagnostic Criteria for Migraine without Aura 18
Table 4: Treatment Guidelines for Migraine 20
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013 21
Table 6: Product Profile - Antidepressants 27
Table 7: Antidepressants SWOT Analysis, 2013 28
Table 8: Global Sales Forecasts ($m) for Antidepressants, 2012-2023 29
Table 9: Physicians Surveyed, By Country 38

1.2 List of Figures

Figure 1: Migraine Treatment Algorithm in the 7MM 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth ...

Global DL-Tryptophan Market Research Report 2016

Global DL-Tryptophan Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global DL-Tryptophan Industry Report is a professional and in-depth research report on the world's major regional market conditions of the DL-Tryptophan industry, focusing on the main regions (North ...

Global L-Tryptophan Market Research Report 2016

Global L-Tryptophan Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global L-Tryptophan Industry Report is a professional and in-depth research report on the world's major regional market conditions of the L-Tryptophan industry, focusing on the main regions (North ...


Download Unlimited Documents from Trusted Public Sources

Antidepressant Market and Bipolar Disorder Statistics in the UK

  • January 2017
    9 pages
  • Antidepressant  

    Bipolar Disorde...  

    Depression  

  • United Kingdom  

View report >

Anti Rheumatic and Analgesic Market in Denmark

  • January 2017
    8 pages
  • Anti Rheumatic  

    Analgesic  

  • Denmark  

    Europe  

View report >

Opioid Market in the US

  • January 2017
    135 pages
  • Opioid  

  • United States  

View report >

Therapy Market

17 days ago

Related Market Segments :

Antidepressant
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.